The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.
作者信息
Rajaram Sanjeeth, Canaday Laura M, Ochayon David E, Rangel Kelly M, Ali Ayad, Gyurova Ivayla E, Krishnamurthy Durga, Fletcher Jonathan S, Reighard Seth D, Cox Andrew, Weirauch Matthew T, Kottyan Leah C, Deshmukh Hitesh, Zacharias William J, Borchers Michael T, Waggoner Stephen N
机构信息
Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Medical Sciences Undergraduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Immunology Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
出版信息
Immunity. 2020 Jun 16;52(6):887-889. doi: 10.1016/j.immuni.2020.04.018. Epub 2020 May 13.
Abstract
摘要
相似文献
1
The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.自然杀伤细胞疗法在肺部感染中的前景与风险
Immunity. 2020 Jun 16;52(6):887-889. doi: 10.1016/j.immuni.2020.04.018. Epub 2020 May 13.
2
Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.双亮型（CD56bright/CD16bright）自然杀伤细胞过继性免疫疗法治疗新型冠状病毒肺炎
Br J Haematol. 2020 Sep;190(6):e322-e323. doi: 10.1111/bjh.17010. Epub 2020 Aug 30.
3
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.过继性免疫疗法的新策略：自然杀伤细胞如何改变老年急性髓细胞白血病患者的治疗方式
Exp Hematol. 2017 Jan;45:10-16. doi: 10.1016/j.exphem.2016.10.007. Epub 2016 Nov 5.
4
Management of severe ARDS due to SARS-CoV-2 pneumonia using low-flow extracorporeal CO extraction.使用低流量体外二氧化碳清除技术治疗新型冠状病毒肺炎所致的重症急性呼吸窘迫综合征
Crit Care. 2021 Oct 18;25(1):362. doi: 10.1186/s13054-021-03777-1.
5
Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.病例报告：CD19 CAR T 细胞治疗后，B 细胞缺陷患者接受恢复期血浆治疗诱导抗 SARS-CoV-2 T 细胞扩增、NK 细胞成熟和病毒清除
Front Immunol. 2021 Aug 12;12:721738. doi: 10.3389/fimmu.2021.721738. eCollection 2021.
6
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.过继性免疫疗法用自然杀伤细胞的长期疗效：同种异体反应性 NK 细胞剂量仍然很重要。
Front Immunol. 2022 Jan 31;12:804988. doi: 10.3389/fimmu.2021.804988. eCollection 2021.
7
NK cell dysfunction in patients with COVID-19.新型冠状病毒肺炎患者的自然杀伤细胞功能障碍
Cell Mol Immunol. 2022 Feb;19(2):127-129. doi: 10.1038/s41423-021-00825-2. Epub 2022 Jan 13.
8
Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias.嵌合抗原受体T细胞和自然杀伤细胞疗法在急性白血病中的应用前景。
Future Oncol. 2016 Oct;12(19):2179-82. doi: 10.2217/fon-2016-0125. Epub 2016 Jun 2.
9
Engineering Natural Killer Cells for Cancer Immunotherapy.用于癌症免疫治疗的工程化自然杀伤细胞
Mol Ther. 2017 Aug 2;25(8):1769-1781. doi: 10.1016/j.ymthe.2017.06.012. Epub 2017 Jun 28.
10
A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.热门话题：癌症免疫疗法与自然杀伤细胞
Int J Mol Sci. 2022 Jan 12;23(2):797. doi: 10.3390/ijms23020797.
引用本文的文献
1
The causal effect of natural killer cells on COVID-19 infection, hospitalization and severity.自然杀伤细胞对新冠病毒感染、住院情况及严重程度的因果效应。
Inflamm Res. 2025 Feb 13;74(1):37. doi: 10.1007/s00011-024-01967-5.
2
Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy.推进自然杀伤细胞疗法：用于增强癌症免疫疗法的基因工程策略。
Ann Lab Med. 2025 Mar 1;45(2):146-159. doi: 10.3343/alm.2024.0380. Epub 2025 Jan 8.
3
Interplay between Lung Diseases and Viral Infections: A Comprehensive Review.肺部疾病与病毒感染之间的相互作用：综述
Microorganisms. 2024 Oct 8;12(10):2030. doi: 10.3390/microorganisms12102030.
4
Ethanolic Extract from (L.) Moench Inhibits Influenza A/B and Respiratory Syncytial Virus Infection : Preventive Agent for Viral Respiratory Infections.来自（L.）Moench的乙醇提取物抑制甲型/乙型流感病毒和呼吸道合胞病毒感染：病毒性呼吸道感染的预防剂
Prev Nutr Food Sci. 2024 Sep 30;29(3):332-344. doi: 10.3746/pnf.2024.29.3.332.
5
Innate Lymphoid Cells and Their Role in the Immune Response to Infections.固有淋巴细胞及其在抗感染免疫中的作用。
Cells. 2024 Feb 13;13(4):335. doi: 10.3390/cells13040335.
6
Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.利用自然杀伤细胞固有免疫对抗血液系统恶性肿瘤：从干细胞移植到过继转移及其他。
Int J Mol Sci. 2022 Dec 22;24(1):204. doi: 10.3390/ijms24010204.
7
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies.我如何治疗和预防血液系统恶性肿瘤患者和细胞治疗受者的 COVID-19。
Blood. 2022 Aug 18;140(7):673-684. doi: 10.1182/blood.2022016089.
8
Single-cell transcriptomics reveal a unique memory-like NK cell subset that accumulates with ageing and correlates with disease severity in COVID-19.单细胞转录组学揭示了一种独特的记忆样 NK 细胞亚群，该亚群随着年龄的增长而积累，并与 COVID-19 中的疾病严重程度相关。
Genome Med. 2022 May 3;14(1):46. doi: 10.1186/s13073-022-01049-3.
9
β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19).β-葡聚糖可作为 SARS-CoV-2 病毒疫苗（COVID-19）佐剂。
Int J Environ Res Public Health. 2021 Nov 30;18(23):12636. doi: 10.3390/ijerph182312636.
10
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.早期 IFN-α 特征和持续功能障碍是严重 COVID-19 中 NK 细胞的显著特征。
Immunity. 2021 Nov 9;54(11):2650-2669.e14. doi: 10.1016/j.immuni.2021.09.002. Epub 2021 Sep 4.
本文引用的文献
1
Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia.新型冠状病毒肺炎外周血淋巴细胞亚群特征变化。
J Infect Dis. 2020 May 11;221(11):1762-1769. doi: 10.1093/infdis/jiaa150.
2
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
3
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
4
Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation.记忆性 CD4 T 细胞衍生的白介素-2 与病毒感染协同作用，加剧肺部炎症。
PLoS Pathog. 2019 Aug 14;15(8):e1007989. doi: 10.1371/journal.ppat.1007989. eCollection 2019 Aug.
5
Natural Killer Cells in the Lungs.肺部自然杀伤细胞。
Front Immunol. 2019 Jun 25;10:1416. doi: 10.3389/fimmu.2019.01416. eCollection 2019.
6
Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.造血细胞移植后仙台病毒在小鼠体内传播、清除及免疫治疗效果的动态变化：无创成像研究
J Virol. 2018 Jan 2;92(2). doi: 10.1128/JVI.01705-17. Print 2018 Jan 15.
7
Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69CD56 cells.人类肺自然杀伤细胞主要由高度分化的低功能 CD69CD56 细胞组成。
J Allergy Clin Immunol. 2017 Apr;139(4):1321-1330.e4. doi: 10.1016/j.jaci.2016.07.043. Epub 2016 Sep 23.
8
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.细胞因子诱导的记忆样自然杀伤细胞对髓系白血病表现出增强的反应。
Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341.
9
Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.白细胞介素-6 抑制自然杀伤细胞细胞毒性：对巨噬细胞活化综合征发病机制的影响。
Arthritis Rheumatol. 2015 Nov;67(11):3037-46. doi: 10.1002/art.39295.
10
Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy.人胎盘来源自然杀伤细胞的鉴定和体外扩增及其在癌症免疫治疗中的应用。
Front Immunol. 2013 May 1;4:101. doi: 10.3389/fimmu.2013.00101. eCollection 2013.
Zotero 插件